{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T13:02:03Z","timestamp":1785589323058,"version":"3.56.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":168,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.schres.2023.05.004","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T04:56:12Z","timestamp":1686286572000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5742-905X","authenticated-orcid":false,"given":"Carlos","family":"De las Cuevas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-4435","authenticated-orcid":false,"given":"Emilio J.","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-2314","authenticated-orcid":false,"given":"Jose","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2023.05.004_bb0005","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther. Adv. Drug. Saf."},{"key":"10.1016\/j.schres.2023.05.004_bb0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/acps.12742","article-title":"International trends in clozapine use: a study in 17 countries","volume":"136","author":"Bachmann","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.05.004_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164304","article-title":"Using rich data on comorbidities in case-control study design with electronic health record data improves control of confounding in the detection of adverse drug reactions","volume":"11","author":"Backenroth","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.schres.2023.05.004_bb0020","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.rpsm.2021.07.004","article-title":"Clozapine-associated myocarditis in the World Health Organization\u2019s pharmacovigilance database: focus on reports from various countries","volume":"15","author":"De Las Cuevas","year":"2022","journal-title":"Rev. Psiquiatr. Salud Ment. (Engl Ed)."},{"key":"10.1016\/j.schres.2023.05.004_bb0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/17512433.2022.2032659","article-title":"Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase","volume":"15","author":"De Las Cuevas","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.05.004_bb0030","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/17425255.2022.2160318","article-title":"Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review","volume":"18","author":"De Las Cuevas","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.schres.2023.05.004_bb0035","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1111\/bcp.15522","article-title":"According to the WHO clozapine pharmacovigilance database, the United Kingdom accounts for 968 fatal outcomes versus 892 in the rest of the world","volume":"88","author":"de Leon","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.05.004_bb0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.24869\/psyd.2022.411","article-title":"Reflections on the complex history of the concept of clozapine-induced inflammation during titration","volume":"34","author":"de Leon","year":"2022","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.schres.2023.05.004_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/schbul\/sbz093","article-title":"Data from the World Health Organization\u2019s pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions","volume":"46","author":"de Leon","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.05.004_bb0050","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000507638","article-title":"A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology","volume":"89","author":"de Leon","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.schres.2023.05.004_bb0055","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/wps.20707","article-title":"Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics","volume":"19","author":"de Leon","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2023.05.004_bb0060","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00406-022-01407-7","article-title":"An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s","volume":"272","author":"de Leon","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2023.05.004_bb0065","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2215-0366(22)00154-7","article-title":"Clozapine and the risk of haematological malignancies","volume":"9","author":"de Leon","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2023.05.004_bb0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels","volume":"55","author":"de Leon","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.05.004_bb0075","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JCP.0000000000001678","article-title":"Escaping the long shadow of agranulocytosis. Reflections on a clozapine pharmacovigilance focused on the United Kingdom","volume":"43","author":"de Leon","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.05.004_bb0080","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2023.05.004_bb0085","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4140\/TCP.n.2022.339","article-title":"Management of Parkinson's disease psychosis","volume":"37","author":"Elsibai","year":"2022","journal-title":"Sr. Care Pharm."},{"key":"10.1016\/j.schres.2023.05.004_bb0090","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/14656566.4.3.319","article-title":"The cost of adverse drug reactions","volume":"4","author":"Gautier","year":"2003","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.schres.2023.05.004_bb0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.rpsm.2020.11.002","article-title":"Amerindians may need clozapine dosing similar to that of Asians","volume":"14","author":"Gonz\u00e1lez-Esquivel","year":"2021","journal-title":"Rev. Psiquiatr. Salud Ment. (Engl Ed)."},{"key":"10.1016\/j.schres.2023.05.004_bb0100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1517\/14740338.2011.562187","article-title":"Use of the self-controlled case series method in drug safety assessment","volume":"10","author":"Grosso","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.schres.2023.05.004_bb0105","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/acps.13406","article-title":"Recognition and management of clozapine adverse effects: a systematic review and qualitative synthesis","volume":"145","author":"Gurrera","year":"2022","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.05.004_bb0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.schres.2023.05.004_bb0115","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(75)90206-8","article-title":"Letter: clozapine and agranulocytosis","volume":"2","author":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2023.05.004_bb0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/10401230309085668","article-title":"Clozapine: a clinical review of adverse effects and management","volume":"15","author":"Iqbal","year":"2003","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.05.004_bb0125","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2165\/00002018-200831080-00007","article-title":"Drug-related deaths: an analysis of the Italian spontaneous reporting database","volume":"31","author":"Leone","year":"2008","journal-title":"Drug Saf."},{"key":"10.1016\/j.schres.2023.05.004_bb0130","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JCP.0000000000001606","article-title":"The modernization of clozapine: a recapitulation of the past in the United States and the view forward","volume":"42","author":"Leung","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.05.004_bb0135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bdi.12272","article-title":"Clozapine for treatment-resistant bipolar disorder: a systematic review","volume":"17","author":"Li","year":"2015","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.schres.2023.05.004_bb0140","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf. J."},{"key":"10.1016\/j.schres.2023.05.004_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-6904-1-3","article-title":"Reporting of adverse drug reactions in randomised controlled trials - a systematic survey","volume":"1","author":"Loke","year":"2001","journal-title":"BMC Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.05.004_bb0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bmj.38701.399942.63","article-title":"Case reports of suspected adverse drug reactions--systematic literature survey of follow-up","volume":"332","author":"Loke","year":"2006","journal-title":"BMJ."},{"key":"10.1016\/j.schres.2023.05.004_bb0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of under-reporting of adverse drug reactions: a systematic review","volume":"32","author":"Lopez-Gonzalez","year":"2009","journal-title":"Drug Saf."},{"key":"10.1016\/j.schres.2023.05.004_bb0160","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1111\/bcp.14851","article-title":"Fatal adverse drug reactions: a worldwide perspective in the World Health Organization pharmacovigilance database","volume":"87","author":"Montastruc","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.05.004_bb0165","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/archinte.167.16.1752","article-title":"Serious adverse drug events reported to the Food and Drug Administration, 1998\u20132005","volume":"167","author":"Moore","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.schres.2023.05.004_bb0170","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40264-012-0014-6","article-title":"WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems","volume":"36","author":"Pal","year":"2013","journal-title":"Drug Saf."},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2023.05.004_bb0175","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.4103\/0976-500X.120955","article-title":"Limitations and obstacles of the spontaneous adverse drugs reactions reporting: two \u201cchallenging\u201d case reports","volume":"4","author":"Palleria","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.schres.2023.05.004_bb0180","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/acps.13066","article-title":"Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies","volume":"140","author":"Papola","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.05.004_bb0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"Br. Med. J."},{"key":"10.1016\/j.schres.2023.05.004_bb0190","first-page":"1036","article-title":"Admissions to hospital caused by adverse drug reactions: cross sectional incidence study","volume":"320","author":"Pouyanne","year":"2000","journal-title":"French Pharmacovigil. Centres Br. Med. J."},{"key":"10.1016\/j.schres.2023.05.004_bb0195","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1097\/MJT.0000000000000894","article-title":"Off-label use of clozapine in children and adolescents-a literature review","volume":"26","author":"Rachamallu","year":"2019","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.schres.2023.05.004_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.15691","article-title":"A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status","author":"Reeves","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.05.004_bb0205","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","article-title":"Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients","volume":"24","author":"Rostami-Hodjegan","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.05.004_bb0210","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.euroneuro.2019.12.118","article-title":"Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials","volume":"32","author":"Rotella","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.05.004_bb0215","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22ac14500","article-title":"Best practices for starting clozapine in patients with schizophrenia: how to switch from the prior antipsychotic(s)","volume":"83","author":"Schoretsanitis","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.05.004_bb0220","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","article-title":"A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients","volume":"12","author":"Schoretsanitis","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.05.004_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f6726","article-title":"Prospective cohort studies: advantages and disadvantages","volume":"347","author":"Sedgwick","year":"2013","journal-title":"BMJ."},{"key":"10.1016\/j.schres.2023.05.004_bb0230","first-page":"153","article-title":"Should we routinely add CRP to clozapine titrations? - learning from three cases","volume":"24","author":"Shelton","year":"2022","journal-title":"Neuropsychopharmacol. Hungarica"},{"key":"10.1016\/j.schres.2023.05.004_bb0235","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/ph15070817","article-title":"Adverse drug reactions in relation to clozapine plasma levels: a systematic review","volume":"15","author":"Skokou","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.schres.2023.05.004_bb0240","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-Year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2023.05.004_bb0245","series-title":"Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor","year":"2021"},{"key":"10.1016\/j.schres.2023.05.004_bb0250","author":"UK Medicines and Healthcare Products Regulatory Agency"},{"key":"10.1016\/j.schres.2023.05.004_bb0255","author":"United States Food and Drug Administration"},{"key":"10.1016\/j.schres.2023.05.004_bb0260","author":"Uppsala Monitoring Centre"},{"key":"10.1016\/j.schres.2023.05.004_bb0265","author":"Uppsala Monitoring Centre"},{"key":"10.1016\/j.schres.2023.05.004_bb0270","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/acps.13267","article-title":"Clozapine and mortality: a comparison with other antipsychotics in a nationwide Danish cohort study","volume":"143","author":"van der Zalm","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.05.004_bb0275","doi-asserted-by":"crossref","first-page":"51","DOI":"10.6061\/clinics\/2017(01)09","article-title":"Effectiveness of pharmacovigilance: multifaceted educational intervention related to the knowledge, skills and attitudes of multidisciplinary hospital staff","volume":"7","author":"Varallo","year":"2017","journal-title":"Clinics (Sao Paulo, Brazil)"},{"key":"10.1016\/j.schres.2023.05.004_bb0280","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1017\/S0033291722001878","article-title":"Ethnic disparities in clozapine prescription for service-users with schizophrenia-spectrum disorders: a systematic review","volume":"52","author":"Ventura","year":"2022","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2023.05.004_bb0285","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/schbul\/sby052","article-title":"Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1\u201312.5\u00a0years","volume":"45","author":"Vermeulen","year":"2019","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.05.004_bb0290","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/acps.13280","article-title":"An evaluation of the variation and underuse of clozapine in the United Kingdom","volume":"143","author":"Whiskey","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.05.004_bb0295","series-title":"The Importance of Pharmacovigilance","author":"World Health Organization","year":"2002"},{"key":"10.1016\/j.schres.2023.05.004_bb0300","author":"World Health Organization"},{"key":"10.1016\/j.schres.2023.05.004_bb0305","article-title":"Schizophrenia plays a negative role in the pathological development of myocardial infarction at multiple biological levels","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.schres.2023.05.004_bb0310","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s002280000158","article-title":"Incidence of lethal adverse drug reactions in the comprehensive hospital drug monitoring, a 20-year survey, 1974\u20131993, based on the data of Berne\/St. Gallen","volume":"56","author":"Zoppi","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423001846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423001846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:43:51Z","timestamp":1700268231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423001846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":62,"alternative-id":["S0920996423001846"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.05.004","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}